When PD-1/L1 treatments first came on the market, there was a race to snaffle as many indications as possible for the therapies. Since then, the market has moved on again and the new competition is to see which company can get a combination therapy onto the market first.
AstraZeneca, notoriously, tried and fail – failing to boost progression-free survival (PFS) in first line non-small cell lung cancer, with its shares tanking by 16% of the news.
